跳至主要内容
临床试验/CTRI/2023/03/051166
CTRI/2023/03/051166招募中Unknown

A Real World Evidence (RWE) Study to Evaluate the Effectiveness of Proton Pump Inhibitors (PPIs) Omeprazole and Pantoprazole for Symptomatic Relief of Gastro-Esophageal Reflux Disease (GERD)/ Acid Peptic Disease (APD) - GERD EMR

Dr. Reddys Laboratories Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
Unknown
状态
招募中
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

入选标准

  • Adult patients aged >=18 years of either gender
  • Patients being newly treated for GERD/APD [treatment naïve patients defined as those patients who have not received (prescribed or self-administered) any anti-acidity or anti-ulcer agent since the last two weeks]
  • Treatment duration of at least 4 weeks with study medication
  • Availability of patient information in Electronic Medical Record (EMR)

排除标准

  • Combinatorial treatment with Proton Pump Inhibitors (PPIs) and prokinetics or antacids within 2 weeks preceding study enrolment
  • Prior treatment with Histamine 2 Receptor Antagonists (H2RAs) within 2 weeks preceding study enrolment
  • Prior treatment with antacids within 2 weeks preceding study enrolment
  • Ongoing treatment with any PPI
  • Refractory GERD already treated with PPI for 6-12 weeks
  • Any condition that, in opinion of the physician, is refractory to treatment with study medications
  • Any condition that, in opinion of the physician, does not justify use of patient-related information in the study

研究者

发起方
Dr. Reddys Laboratories Ltd

相似试验

Real World Data will be collected using Electronic... | 临床试验